Edition:
India

GBT Announces Updated 24-Week Efficacy Data From Phase 3 HOPE Study


Friday, 14 Jun 2019 

June 14 (Reuters) - Global Blood Therapeutics Inc ::GBT ANNOUNCES UPDATED 24-WEEK EFFICACY DATA FROM ALL PATIENTS ENROLLED IN PHASE 3 HOPE STUDY SHOWING STATISTICALLY SIGNIFICANT AND SUSTAINED IMPROVEMENTS IN HEMOGLOBIN WITH VOXELOTOR.GLOBAL BLOOD THERAPEUTICS INC - VOXELOTOR PROVIDED A RAPID, STATISTICALLY SIGNIFICANT AND SUSTAINED IMPROVEMENT IN HEMOGLOBIN LEVELS.GLOBAL BLOOD THERAPEUTICS INC - VOXELOTOR REDUCED INCIDENCE OF WORSENING ANEMIA AND HEMOLYSIS.GLOBAL BLOOD THERAPEUTICS INC - REACHED FINAL AGREEMENT WITH FDA ON DESIGN OF OUR TRANSCRANIAL DOPPLER POST-APPROVAL CONFIRMATORY STUDY.